USA - NASDAQ:RDNT - US7504911022 - Common Stock
The current stock price of RDNT is 76.1 USD. In the past month the price decreased by -2.85%. In the past year, price increased by 14.37%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.2 | 97.27B | ||
| CI | THE CIGNA GROUP | 8.8 | 65.96B | ||
| LH | LABCORP HOLDINGS INC | 15.95 | 20.97B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 203.73 | 19.85B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.01 | 19.65B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.21 | 15.66B | ||
| HIMS | HIMS & HERS HEALTH INC | 55.08 | 9.96B | ||
| DVA | DAVITA INC | 12.24 | 8.49B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.52B | ||
| CHE | CHEMED CORP | 20.66 | 6.62B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 59.62 | 5.81B | ||
| OPCH | OPTION CARE HEALTH INC | 19.41 | 4.25B | 
 RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 8,546 full-time employees. The company went IPO on 2001-12-12. The firm has a network of 401 owned and/or operated outpatient imaging centers. The Company’s Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand. The company is also a provider of AI-powered breast health solutions.
RADNET INC
1510 Cotner Ave
Los Angeles CALIFORNIA 90025 US
CEO: Howard G. Berger
Employees: 8773
Phone: 13104787808
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 8,546 full-time employees. The company went IPO on 2001-12-12. The firm has a network of 401 owned and/or operated outpatient imaging centers. The Company’s Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand. The company is also a provider of AI-powered breast health solutions.
The current stock price of RDNT is 76.1 USD. The price decreased by -3.48% in the last trading session.
RDNT does not pay a dividend.
RDNT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
RDNT stock is listed on the Nasdaq exchange.
RADNET INC (RDNT) has a market capitalization of 5.85B USD. This makes RDNT a Mid Cap stock.
You can find the ownership structure of RADNET INC (RDNT) on the Ownership tab.
ChartMill assigns a technical rating of 7 / 10 to RDNT. When comparing the yearly performance of all stocks, RDNT is one of the better performing stocks in the market, outperforming 84.08% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to RDNT. Both the profitability and the financial health of RDNT get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months RDNT reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS decreased by -36.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.42% | ||
| ROE | -1.6% | ||
| Debt/Equity | 1.16 | 
13 analysts have analysed RDNT and the average price target is 80.87 USD. This implies a price increase of 6.27% is expected in the next year compared to the current price of 76.1.
For the next year, analysts expect an EPS growth of -34.83% and a revenue growth 8.63% for RDNT